Journal of Hepatology
Volume 51, Issue 4 , Pages 640-646 , October 2009

Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B

  • Maria Buti

      Affiliations

    • Servicio de Hepatologı´a, Hospital Vall d’Hebrón and Ciber-ehd del Instituto Carlos III, Barcelona, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34 93 2746140; fax: +34 93 2746068.
    • ,
  • Max Brosa

      Affiliations

    • Oblikue Consulting, Barcelona, Spain
    • ,
  • Miguel A. Casado

      Affiliations

    • Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
    • ,
  • Magdalena Rueda

      Affiliations

    • Gilead Sciences Inc., Madrid, Spain
    • ,
  • Rafael Esteban

      Affiliations

    • Servicio de Hepatologı´a, Hospital Vall d’Hebrón and Ciber-ehd del Instituto Carlos III, Barcelona, Spain

Received 19 January 2009 ,Revised 16 March 2009 ,Accepted 1 April 2009.

References 

  1. Ganem D, Prince AM. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129
  2. Lok ASF, McMahon BJ. Chronic hepatitis B; AASLD practice guidelines. Hepatology. 2007;45:507–539
  3. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok ASF. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056–1075
  4. Brown R, Cock E, Colin X, Antoñanzas F, Iloeje U. Hepatitis B management costs in France, Italy, Spain and the United Kingdom. J Clin Gastroenterol. 2004;38:S169–S174
  5. Idris BI, Brosa M, Richardus JH, Esteban R, Schalmb SW, Buti M. Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain. Eur J Gastroenterol Hepatol. 2008;20:320–326
  6. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  7. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003;37:1309–1319
  8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  9. EASL Guidelines European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227–42.
  10. Marcellin P, Heathcote EJ, Buti M, Gane E, DeMan R, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455
  11. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001–1010
  12. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  13. Peters MG, Hann HW, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004;126:91–101
  14. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006;354:1011–1020
  15. Liaw YF, Leung N, Guan R, Lau GKK, Merican I, McCaughan G, et al. For the Asian Pacific consensus update working party of chronic hepatitis B. Liver Int. 2005;25:472–489
  16. Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology. 2007;133:1445–1451
  17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131:1743–1751
  18. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495
  19. Marcellin P, Buti M, Kratev Z, Gural S, Balabanska RI, Dusheiko G, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis. Hepatology. 2008;48:370A
  20. Heathcote E, Gane EJ, de Man RA, Chang S, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis. Hepatology. 2008;48(suppl):376A
  21. Van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006;44:318–325
  22. Van Bömmel F, Wunsche T, Mauss S, Reinke P, Bergk A, Schurmann D, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421–1425
  23. Van Bömmel F, de Man RA, Stein K, Hüuppe D, Petersen J, Buggisch P, et al. A multicenter analysis of antiviral response after one year of tenofovir mono-therapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J Hepatol. 2008;48:S32
  24. Snow-Lampart A, Chappell BJ, Curtis M, Zhu Y, Heathcote E, Marcellin P, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300mg QD. Hepatology. 2008;48:745A
  25. Han B, Chang TT, Chao YT, Yoon SK, Gish RG, Cheinquer H, et al. Five years of continuous entecavir for nucleoside-naı¨ve HBeAg (+) chronic hepatitis B: results from Study ETV-901. Hepatology. 2008;48:705A
  26. Van Bömmel F, Feucht H, Schlosser B, Weich V, Schott E, Wiedenmann B, et al. Detection of mutations associated with resistance to nucleos(t)ide analogs in patients with HBV infection during treatment with tenofovir. Hepatology. 2008;48:715A
  27. López Bastida J, Oliva J, Antoñanzas F, Garcı´a-Altés A, Gisbert R, Mar J, et al. Propuesta de guı´a para la evaluación económica aplicada a las tecnologı´as sanitarias. Madrid: Plan Nacional para el SNS del MSC. Servicio de Evaluación del Servicio Canario de la Salud; 2008. Informes de Evaluación de Tecnologı´as Sanitarias: SESCS No. 2006/22. Available from: http://aunets.isciii.es/ficherosproductos/132/MemoriaFinal.pdf.
  28. Herdman M, Ossa D, Briggs A, Casanovas T, Garcı´a-Samaniego J, Fusté LC, et al. Measuring preferences for health states resulting from chronic hepatits B infection in a Spanish population. In: 12th international symposium on viral hepatitis and liver disease. Paris, July 1–5; 2006.
  29. Claxton K, Schupher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ. 2005;14:339–347
  30. Sun X, Qin WX, Li YP, Jiang XH. Comparative cost-effectiveness of antiviral therapies in patients with chronic hepatitis B: a systematic review of economic evidence. J Gastroenterol Hepatol. 2007;22:1369–1377
  31. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005;142:821–831
  32. Buti M, Casado MA, Calleja JL, Salmerón J, Aguilar J, Rueda M, et al. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B. Aliment Pharmacol Ther. 2006;23:409–419
  33. Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 2007;25:963–977

☆ This study was supported in part by a research grant from Gilead Sciences. The authors had independence from the funding company in study design, analysis and interpretation of the data, report writing, and publication, regardless of the results. M. Brosa is an employee of Oblikue Consulting; M.C. is an employee of Pharmaeconomics & Outcomes Research Iberia; M.R. is an employee of Gilead Sciences Inc.; M. Buti, M. Brosa and R. Esteban are on the Advisory board for Gilead, Novartis. Speaker: Gilead, Novartis, Bristol-Myers Squibb and Schering-Plough.

PII: S0168-8278(09)00322-5

doi: 10.1016/j.jhep.2009.04.013

Journal of Hepatology
Volume 51, Issue 4 , Pages 640-646 , October 2009

Article Tools

* Image Usage & Resolution